Drug intelligence / Profile preview

KNP-2002

Development stage: Phase 2
Lead developer: KinoPharma
Modality: Small Molecules
Administration: Topical

Overview

KNP-2002 is a small molecule drug developed by KinoPharma for the treatment of common warts. It is currently in Phase 2 clinical trials for this indication. The drug is being evaluated as a topical ointment for patients with common warts, primarily targeting infectious diseases and skin and musculoskeletal diseases. While the precise mechanism of action has not been disclosed in public sources, it is under active investigation as a novel therapy for warts[1][2][5].

Other names: HPV 2/27/57 antiviral ointmentKinoPharma common warts treatment

Targets

HPV-57 (Human papillomavirus type 57)HPV-2 (Human papillomavirus type 2)

Beyond the preview

Go deeper on KNP-2002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNP-2002.

Explore the full profile